Acrux: Result 2014

This small pharmaceutical stock has confounded the sceptics again, with sales of its flagship Axiron product rising 46%, despite an FDA investigation.

Pharmaceutical companies are supposed to abide by the principle of primum non nocere – first, do no harm. But Acrux’s full-year result was painful to read. Or at least it was for me, and probably anyone else who missed the boat. But for members who managed to scramble on board when we recommended the stock in Ignore the FDA and buy Acrux on 13 Jun 14 (Speculative Buy – $0.80), rest assured, your company had a bumper year.


SMS Code Sent…

We have sent you a code via SMS to {{user.DayPhone}}

please enter this code below to activate your membership

If you didn't receive SMS code please

Log in to access this content

Looks you are already a member. Please enter your password to proceed

Hi {{ user.FirstName }}

Verify your mobile number to unlock a FREE trial

Looks like you've already taken a free trial

Please sign up for full access

Updating information

Please wait ...

Related Articles